Clinical trial · Interventional
Camrelizumab Utilization on Patients With Advanced Liver Cancer
A Real World Study of Treatment Regimens Containing Camrelizumab in Patients With Advanced Liver Cancer
NCT04487704CI-TRIAL-00058141unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To observe and evaluate the safety and efficacy of camrelizumab in advanced liver cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| camrelizumab | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Camrelizumab in the treatment of liver cancer
- description
- Camrelizumab intravenous infusion (no need for prophylactic administration), no less than 30 min
- interventionNames
- Other: camrelizumab
Primary outcomes (1)
- measure
- Assess Safety as defined by the NCI CTCAE v5.0
- timeFrame
- From patients participate in the clinical study to 90 days after the end of treatment
- description
- Adverse events as graded by CTCAE v5.0
Secondary outcomes (1)
- measure
- overall survival
- timeFrame
- 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years old or more; * For both men and women; * Patients with advanced liver cancer confirmed by histopathology or cytology; .Volunteer to join the study, sign the informed consent, good compliance, and cooperate with the follow-up. Exclusion Criteria: * A known allergy to the study drug or any of its excipients; Or had a severe allergic reaction to other monoclonal antibodies; * Patients who are ready for or have previously received an organ or allogeneic bone marrow transplant; * Pregnant or lactating women; * According to the judgment of the researcher, the patients should not be included in this study
References
Publications (0)
Data not yet available
No reference posted for this study.